Barrett's esophagus natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
 
(9 intermediate revisions by one other user not shown)
Line 10: Line 10:
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
===Natural History===
===Natural History===
An increased risk of [[esophageal cancer]]. Follow-up [[endoscopy]] to look for [[dysplasia]] or [[cancer]] is often advised.
Barrett's esophagus is associated with increased risk of [[esophageal cancer]]. Follow-up [[endoscopy]] is recommended for [[dysplasia]] or [[cancer]] evaluation.
*The symptoms of [[Barrett's esophagus]] usually develop in the fifth/sixth decade of life, and start with symptoms of [[GERD]] such as [[heartburn]], [[regurgitation]] and [[dysphagia]].
*The symptoms of Barrett's esophagus usually develop in the fifth/sixth decade of life, and start with symptoms of [[GERD]] such as [[heartburn]], [[regurgitation]] and [[dysphagia]].  
*The symptoms of (disease name) typically develop ___ years after exposure to ___.  
*If left untreated, 100 to 400 out of 100,000 patients with [[Barrett's esophagus]] may progress to develop [[Esophageal Cancer|esophageal adenocarcinoma]]. <ref name="pmid9040193">{{cite journal| author=Drewitz DJ, Sampliner RE, Garewal HS| title=The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. | journal=Am J Gastroenterol | year= 1997 | volume= 92 | issue= 2 | pages= 212-5 | pmid=9040193 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9040193  }} </ref><ref name="pmid11448658">{{cite journal| author=Eckardt VF, Kanzler G, Bernhard G| title=Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. | journal=Am J Med | year= 2001 | volume= 111 | issue= 1 | pages= 33-7 | pmid=11448658 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11448658  }} </ref><ref name="pmid18045592">{{cite journal| author=Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P| title=Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. | journal=Gastrointest Endosc | year= 2008 | volume= 67 | issue= 3 | pages= 394-8 | pmid=18045592 | doi=10.1016/j.gie.2007.07.019 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18045592  }} </ref><ref name="pmid16630761">{{cite journal| author=Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE| title=Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. | journal=Clin Gastroenterol Hepatol | year= 2006 | volume= 4 | issue= 5 | pages= 566-72 | pmid=16630761 | doi=10.1016/j.cgh.2006.03.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16630761  }} </ref><ref name="pmid21997553">{{cite journal| author=Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S et al.| title=The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. | journal=Gut | year= 2012 | volume= 61 | issue= 7 | pages= 970-6 | pmid=21997553 | doi=10.1136/gutjnl-2011-300730 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21997553  }} </ref>
*If left untreated, 0.1% to 0.4% of patients per year with [[Barrett's esophagus]] may progress to develop [[esophageal adenocarcinoma]]<ref name="pmid9040193">{{cite journal| author=Drewitz DJ, Sampliner RE, Garewal HS| title=The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. | journal=Am J Gastroenterol | year= 1997 | volume= 92 | issue= 2 | pages= 212-5 | pmid=9040193 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9040193  }} </ref><ref name="pmid11448658">{{cite journal| author=Eckardt VF, Kanzler G, Bernhard G| title=Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. | journal=Am J Med | year= 2001 | volume= 111 | issue= 1 | pages= 33-7 | pmid=11448658 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11448658  }} </ref><ref name="pmid18045592">{{cite journal| author=Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P| title=Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. | journal=Gastrointest Endosc | year= 2008 | volume= 67 | issue= 3 | pages= 394-8 | pmid=18045592 | doi=10.1016/j.gie.2007.07.019 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18045592  }} </ref>.


===Complications===
===Complications===
Line 21: Line 20:
**[[Esophageal]] [[ulcers]]<ref name="pmid22826612">{{cite journal| author=Milind R, Attwood SE| title=Natural history of Barrett's esophagus. | journal=World J Gastroenterol | year= 2012 | volume= 18 | issue= 27 | pages= 3483-91 | pmid=22826612 | doi=10.3748/wjg.v18.i27.3483 | pmc=3400849 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22826612  }} </ref>
**[[Esophageal]] [[ulcers]]<ref name="pmid22826612">{{cite journal| author=Milind R, Attwood SE| title=Natural history of Barrett's esophagus. | journal=World J Gastroenterol | year= 2012 | volume= 18 | issue= 27 | pages= 3483-91 | pmid=22826612 | doi=10.3748/wjg.v18.i27.3483 | pmc=3400849 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22826612  }} </ref>


Progression
=== Progression ===
* From low-grade [[dysplasia]] to high-grade [[dysplasia]] or [[esophageal]] [[adenocarcinoma]]: 0.5 to 13.4% per [[year]]
* From low-grade [[dysplasia]] to high-grade [[dysplasia]] or [[esophageal]] [[adenocarcinoma]]: 0.5 to 13.4% per [[year]]
* From high-grade [[dysplasia]] to [[cancer]]: 6% per [[year]].<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>
* From high-grade [[dysplasia]] to [[cancer]]: 6% per [[year]]<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>


==Prognosis==
==Prognosis==
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*[[Prognosis]] is generally good for [[Barrett's esophagus]], but if it is associated with [[esophageal]] [[adenocarcinoma]] then 5 year survival rate of [[patients]] with [[Barrett's esophagus]] is approximately 20%.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.


==References==
==References==

Latest revision as of 17:25, 21 February 2018

Barrett's Esophagus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Barrett's esophagus natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus natural history, complications and prognosis

CDC on Barrett's esophagus natural history, complications and prognosis

Barrett's esophagus natural history, complications and prognosis in the news

Blogs on Barrett's esophagus natural history, complications and prognosis

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amresh Kumar MD [2]

Overview

Common complications of Barrett's esophagus include esophageal carcinoma, esophageal stricture and esophageal ulcers.

Natural History, Complications, and Prognosis

Natural History

Barrett's esophagus is associated with increased risk of esophageal cancer. Follow-up endoscopy is recommended for dysplasia or cancer evaluation.

Complications

Progression

Prognosis

References

  1. Drewitz DJ, Sampliner RE, Garewal HS (1997). "The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years". Am J Gastroenterol. 92 (2): 212–5. PMID 9040193.
  2. Eckardt VF, Kanzler G, Bernhard G (2001). "Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation". Am J Med. 111 (1): 33–7. PMID 11448658.
  3. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P (2008). "Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis". Gastrointest Endosc. 67 (3): 394–8. doi:10.1016/j.gie.2007.07.019. PMID 18045592.
  4. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE (2006). "Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus". Clin Gastroenterol Hepatol. 4 (5): 566–72. doi:10.1016/j.cgh.2006.03.001. PMID 16630761.
  5. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S; et al. (2012). "The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis". Gut. 61 (7): 970–6. doi:10.1136/gutjnl-2011-300730. PMID 21997553.
  6. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P (2011). "Incidence of adenocarcinoma among patients with Barrett's esophagus". N Engl J Med. 365 (15): 1375–83. doi:10.1056/NEJMoa1103042. PMID 21995385.
  7. 7.0 7.1 Milind R, Attwood SE (2012). "Natural history of Barrett's esophagus". World J Gastroenterol. 18 (27): 3483–91. doi:10.3748/wjg.v18.i27.3483. PMC 3400849. PMID 22826612.
  8. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter |month= ignored (help)
  9. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Template:WH Template:WS